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Hepatobiliary contrast agents currently are essentially
gadolinium based agents (Gd-EOB-DTPA and Gd-
BOPTA) with dual ability to perform dynamic contrast
enhanced imaging similar to extracellular gadolinium
contrast as well as providing hepatobiliary uptake and
excretion in later phases. Hepatobiliary uptake and excre-
tion with gadoxetic acid (Gd-EOB-DTPA) is related to
OATP and cMOAT and MRP2 receptors presence on
hepatocytes. Since gadoxetic acid has a recommended
dose which is 25 %( 0.025mmol/kg) of Gd-DTPA atten-
tion to technical parameters is crucial. Improved arterial
phase enhancement is obtained by MR fluoroscopic or
bolus-tracking type triggering technique and either a
lower injection flow rate of 1 mL/s or less as opposed to
2 mL/s, or contrast dilution. To improve liver-lesion con-
trast-to-noise ratio, 3D T1-weighted gradient-echo acqui-
sition for the hepatobiliary phase should be performed
with higher flip angles (20-35°). In order to optimize
workflow, Diffusion-weighted and T2-weighted imaging
can be performed after gadoxetic acid administration
without compromising diagnostic capability; however,
MRCP pulse sequences should be acquired before the
contrast injection.
The clinical utilization of Hepatobiliary contrast agents
is predominantly for staging of liver metastases, characteri-
zation of hepatocellular lesions such as adenoma and FNH
as well as diagnosis of HCC and cirrhosis related nodules.
In the preoperative setting for accurate evaluation of col-
orectal liver metastases and appropriate surgical planning,
gadoxetic acid-enhanced liver MRI is recommended
because it has superior sensitivity and specificity compared
to ultrasound, PET, and CT. In the assessment of patients
with colorectal liver metastases who have been treated
with chemotherapy, preoperative imaging with gadoxetic
acid may be of particular benefit. For the differentiation of
focal nodular hyperplasia from hepatic adenoma, gadoxetic
acid-enhanced MRI should be considered due to its discri-
minative ability between the two based on hepatobiliary
phase features. The combination of hypointensity on hepa-
tobiliary phase images and mild-to-moderate arterial
enhancement for adenoma versus strong enhancement on
arterial phase images and iso- or hyperintensity on hepato-
biliary phase images for FNH showed sensitivity and
specificity of 83.7% and 100% and 83.8% and 98.5%,
respectively. However a small percentage of adenomas can
exhibit hepatobiliary uptake and surveillance and or biopsy
should be considered when imaging appearances are not
typical. Although gadoxetic acid-enhanced MRI yields sig-
nificantly higher diagnostic accuracy and sensitivity com-
pared with multiphasic CT for the diagnosis of HCC in
cirrhosis, its role in the clinical management of HCC has
yet to be defined in North America while it has seen wide-
spread implementation in Asia/Japan. There is insufficient
evidence supporting cost-effectiveness or outcomes for
recommending the utilization of gadoxetic acid-enhanced
MRI for HCC screening at this time. A significant percen-
tage of nodules with hepatobiliary phase hypoenhance-
ment but atypical enhancement on the dynamic phases
have been associated with a diagnosis of HCC or future
development of HCC. Biopsy or close surveillance of these
lesions is recommended. Off label applications include
evaluation of biliary disorders, bile leaks and hepatic func-
tion. Gadoxetic acid-enhanced liver MRI is an evolving
technique with potential for non-invasive quantification of
liver function and staging of hepatic fibrosis.
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